Risk Disclosure: This website's content is not investment advice and offers no trading guidance or related services. Per regulations from the PBOC and other authorities, users must be aware of virtual currency risks. Contact us / support@techflowpost.com ICP License: 琼ICP备2022009338号
TechFlow news, September 2 — Biopharmaceutical company Propanc Biopharma (Nasdaq: PPCB) announced today (September 2) plans to acquire $100 million worth of Ethereum within the next 12 months. The company stated this move will strengthen its corporate strategy across multiple areas, including cryptocurrency investments, drug development, and asset acquisitions.
Biopharmaceutical company Propanc Biopharma (NASDAQ: PPCB) announced today (September 2) its plan to acquire $100 million worth of Ethereum within the next 12 months. The company stated that this move will strengthen its corporate strategy across multiple areas, including cryptocurrency investments, drug development, and asset acquisitions.
Navigating Web3 tides with focused insights
